Nesiritide (Natrecor)

1. Overview

Nesiritide is the recombinant form of human B-type natriuretic peptide (BNP, also known as brain natriuretic peptide), a 32-amino acid cardiac hormone produced primarily by ventricular cardiomyocytes in response to myocardial wall stress from volume overload and pressure overload [6][15]. Marketed as Natrecor by Scios Inc. (a subsidiary of Johnson and Johnson), nesiritide was FDA-approved in August 2001 for the intravenous treatment of patients with acutely decompensated heart failure (ADHF) who have dyspnea at rest or with minimal activity [8][16].

The molecular formula of nesiritide is C143H244N50O42S4 with a molecular weight of 3464 Da. The peptide is identical in amino acid sequence to endogenous human BNP-32, including the characteristic 17-residue disulfide-bridged ring structure formed between Cys10 and Cys26, which is essential for biological activity at the natriuretic peptide receptor A (NPR-A) [6][7][15]. Nesiritide is produced by recombinant DNA technology in Escherichia coli.

The clinical story of nesiritide is one of the most instructive cautionary tales in cardiovascular medicine. Following rapid adoption after its 2001 approval based on hemodynamic and symptomatic endpoints, two influential meta-analyses in 2005 raised alarm about possible worsening of renal function and increased mortality, triggering a dramatic decline in use [3][4][12][13]. The definitive ASCEND-HF trial (n=7,141), the largest acute heart failure trial ever conducted at that time, ultimately resolved the safety controversy by showing no harm -- but also demonstrated only marginal symptomatic benefit and no effect on mortality or rehospitalization, effectively marginalizing nesiritide's clinical role [2].

Type

Recombinant B-type natriuretic peptide (32 amino acids)

Molecular Weight

3464 Da

Molecular Formula

C₁₄₃H₂₄₄N₅₀O₄₂S₄

Structure

32 AA peptide with 17-residue disulfide-bridged ring (Cys10-Cys26)

Half-life

~18-20 minutes (intravenous)

Clearance

Neutral endopeptidase (neprilysin), NPR-C receptor, renal filtration

Routes

Intravenous (bolus then continuous infusion)

FDA Status

Approved (Natrecor, August 2001 for ADHF)

Approved Indication

Acute decompensated heart failure with dyspnea at rest or minimal exertion

2. Discovery and Natriuretic Peptide Biology

2.1 The Natriuretic Peptide System

The natriuretic peptide system was discovered through a series of landmark studies beginning with de Bold and colleagues' observation in 1981 that atrial myocardial extracts produced a rapid and potent natriuretic response when injected intravenously into rats [14]. This led to the identification of atrial natriuretic peptide (ANP). In 1988, Sudoh and colleagues isolated a second natriuretic peptide from porcine brain tissue, naming it "brain natriuretic peptide" (BNP) [6]. Despite the name, subsequent research revealed that BNP is synthesized predominantly in cardiac ventricular myocytes rather than in the brain, with production upregulated in response to ventricular wall stretch and volume overload [15].

Human BNP is initially produced as a 134-amino acid preprohormone (preproBNP), which is cleaved to the 108-amino acid proBNP, and then further processed by the serine protease corin and furin to yield the biologically active 32-amino acid BNP-32 and the inactive N-terminal fragment NT-proBNP [15]. Both BNP and NT-proBNP serve as clinical biomarkers for heart failure diagnosis and risk stratification.

2.2 NPR-A Signaling and Cardiovascular Effects

BNP (and therefore nesiritide) exerts its biological effects primarily through binding to natriuretic peptide receptor A (NPR-A, also known as guanylyl cyclase A or GC-A), a transmembrane receptor with intrinsic guanylyl cyclase activity [7][15]. Binding activates the intracellular catalytic domain, generating cyclic GMP (cGMP), which activates cGMP-dependent protein kinase II (PKG-II), leading to:

• Vasodilation. Smooth muscle relaxation via PKG-mediated phosphorylation of myosin light chain phosphatase, producing balanced arterial and venous vasodilation. Reduces both preload and afterload [15].
• Natriuresis and diuresis. Increased renal sodium and water excretion through suppression of sodium reabsorption in the inner medullary collecting duct and increased GFR [15].
• RAAS suppression. Direct inhibition of renin secretion from juxtaglomerular cells and aldosterone secretion from the adrenal zona glomerulosa [15].
• Sympatholytic effects. Attenuation of sympathetic nervous system activation.
• Antifibrotic and antihypertrophic effects. Inhibition of cardiac fibroblast proliferation and collagen synthesis via cGMP/PKG signaling [7].

BNP is cleared from the circulation through three mechanisms with approximately equal contributions: (1) neutral endopeptidase (neprilysin) degradation, (2) NPR-C (clearance receptor) internalization, and (3) renal filtration [15]. The plasma half-life of nesiritide is approximately 18-20 minutes [16].

3. Clinical Development and Controversy

3.1 Early Development and Approval

Scios Inc. developed nesiritide (initially BNP-32) as a therapeutic agent for acute heart failure. The initial Phase 2 study (Colucci et al., 2000) demonstrated rapid hemodynamic improvement in 127 patients with ADHF, with dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic vascular resistance [8].

The pivotal VMAC trial (Vasodilation in the Management of Acute CHF, 2002) randomized 489 patients with ADHF to nesiritide, intravenous nitroglycerin, or placebo [1]. Nesiritide produced significantly greater reductions in PCWP at 3 hours compared to nitroglycerin (-5.8 vs -3.8 mmHg; p=0.03) and placebo (-5.8 vs -2.0 mmHg; p=0.001). Self-reported dyspnea improvement at 3 hours was significantly greater versus placebo but not versus nitroglycerin. Based primarily on these hemodynamic and symptomatic endpoints, the FDA approved nesiritide in August 2001 [1].

3.2 Rapid Adoption

Following approval, nesiritide use expanded rapidly, with annual US sales reaching approximately $700 million by 2004. The drug was widely adopted in emergency departments and intensive care units as an alternative to nitroglycerin and dobutamine for ADHF management [13].

3.3 The Safety Controversy (2005)

In 2005, Jonathan Sackner-Bernstein and colleagues published two influential meta-analyses that fundamentally altered the nesiritide landscape [3][4]:

Renal risk meta-analysis: Pooling data from 5 RCTs (1,269 patients), they found that nesiritide was associated with significantly increased risk of worsening renal function (risk ratio 1.52; 95% CI 1.16-2.00; p=0.003) [3].

Mortality risk meta-analysis: Pooling data from 3 RCTs (862 patients), they identified a trend toward increased 30-day mortality with nesiritide (risk ratio 1.74; 95% CI 0.97-3.12; p=0.059) [4]. While not reaching statistical significance, this finding generated enormous concern.

These analyses, combined with an influential editorial by Eric Topol entitled "Nesiritide -- Not Verified" [12], triggered a precipitous decline in nesiritide use. Annual sales fell from approximately $700 million to approximately $100 million within two years [13]. The FDA convened an advisory committee and mandated a large outcomes trial to definitively address safety concerns.

3.4 ASCEND-HF: The Definitive Answer

The ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure, O'Connor et al., 2011) was designed specifically to answer whether nesiritide increased mortality or worsened renal function [2][11]. This landmark trial randomized 7,141 patients hospitalized for ADHF across 398 sites in 30 countries to nesiritide or placebo, both added to standard care.

Key results at 30 days [2]:

• Primary endpoint (all-cause mortality or HF rehospitalization): 9.4% nesiritide vs 10.1% placebo (absolute difference -0.7%; p=0.31) -- no significant difference.
• 30-day mortality: 3.6% vs 4.0% (HR 0.90; 95% CI 0.68-1.18; p=0.44) -- no excess mortality.
• Worsening renal function: 31.4% vs 31.0% (p=0.89) -- no excess renal harm, directly contradicting the Sackner-Bernstein meta-analysis.
• Dyspnea at 6 and 24 hours: Modest but statistically significant improvement (p=0.007 at 6 hours), though the absolute benefit was small.
• Hypotension: 26.6% vs 15.3% (p not reported, but clearly more frequent).

ASCEND-HF effectively resolved the safety controversy -- nesiritide was neither harmful to kidneys nor associated with increased mortality. However, it also demonstrated that nesiritide provided only marginal symptomatic benefit and no reduction in hard clinical outcomes (mortality, rehospitalization), fundamentally undermining the rationale for its routine use [2].

4. Clinical Evidence Summary

5. Dosing in Research

Standard ADHF protocol. Nesiritide 2 mcg/kg intravenous bolus over 60 seconds, followed by continuous infusion at 0.01 mcg/kg/min. The infusion may be increased by 0.005 mcg/kg/min every 3 hours as tolerated, up to a maximum of 0.03 mcg/kg/min. Bolus is preceded by priming the IV tubing with 25 mL of the infusion solution. Maximum recommended infusion duration is 48 hours [16].

Dose adjustment. If symptomatic hypotension occurs, the infusion should be reduced or discontinued. Nesiritide should not be initiated at systolic blood pressure below 90 mmHg [16].

Blood pressure monitoring. Blood pressure should be monitored closely, particularly within the first hour after initiation when hypotensive effects are most pronounced [16].

ROSE-AHF low-dose protocol. 0.005 mcg/kg/min continuous infusion without bolus, tested in patients with ADHF and renal dysfunction. This low-dose strategy did not improve outcomes [10].

6. Safety and Side Effects

Hypotension. The most clinically significant adverse effect. In ASCEND-HF, symptomatic hypotension occurred in 26.6% of nesiritide-treated patients versus 15.3% of placebo patients. Hypotension is dose-dependent and related to the vasodilatory mechanism [2][16].

Renal effects. Despite initial meta-analysis concerns, ASCEND-HF definitively demonstrated no excess worsening of renal function (serum creatinine increase of 0.5 mg/dL or more) compared to placebo [2]. The ROSE-AHF trial confirmed that low-dose nesiritide does not improve renal function in cardiorenal syndrome [10].

Headache. Reported in 4-8% of patients, consistent with vasodilatory effects [16].

Nausea. Occurs in approximately 4% of patients [16].

Cardiac arrhythmias. The PRECEDENT trial showed fewer ventricular arrhythmias with nesiritide compared to dobutamine (1% vs 12%), a potential advantage over inotrope therapy [9].

Contraindications. Cardiogenic shock, systolic blood pressure below 90 mmHg, hypersensitivity to nesiritide or E. coli-derived proteins. Should not be used as primary therapy for cardiogenic shock or as a substitute for diuretics [16].

7. Place in Current Therapy

Following ASCEND-HF, nesiritide's role in heart failure management has become marginal [19][20]:

• The 2013 ACCF/AHA Heart Failure Guidelines gave nesiritide only a Class IIb recommendation ("may be considered to improve symptoms") for patients with ADHF not responding to diuretics, emphasizing that it should not be used to enhance diuresis or improve renal function [19].
• Most contemporary heart failure algorithms prioritize IV loop diuretics (optimized dosing per the DOSE trial) as first-line therapy for ADHF, with nitroglycerin for hypertensive emergencies and milrinone/dobutamine reserved for cardiogenic shock [18][19].
• The paradigm shift toward neurohormonal modulation of the natriuretic peptide system was ultimately realized not through exogenous BNP administration (nesiritide) but through neprilysin inhibition with sacubitril/valsartan (Entresto), which prevents degradation of endogenous natriuretic peptides and demonstrated dramatic mortality reduction in the PARADIGM-HF trial [17].

8. Legacy and Lessons

Nesiritide's trajectory from blockbuster to clinical footnote offers important lessons for drug development and evidence-based medicine:

1. Surrogate endpoints are insufficient. FDA approval based on hemodynamic improvements (PCWP reduction) and subjective dyspnea relief did not translate to meaningful clinical outcomes.
2. Meta-analyses can mislead. The Sackner-Bernstein meta-analyses, while methodologically sound, were based on limited and heterogeneous data. The definitive ASCEND-HF trial refuted the renal and mortality concerns.
3. Large outcomes trials are essential. Only ASCEND-HF (n=7,141) provided the statistical power to definitively assess nesiritide's efficacy and safety.
4. Neprilysin inhibition succeeded where exogenous BNP failed. The natriuretic peptide pathway proved therapeutically valuable, but the approach of potentiating endogenous natriuretic peptides (sacubitril/valsartan) was superior to exogenous administration [17].

9. Pharmacokinetics

Intravenous Pharmacokinetics

Nesiritide exhibits rapid-onset, short-duration pharmacokinetics consistent with an endogenous 32-amino acid peptide administered intravenously [8][15][16].

Distribution. Following IV bolus administration, nesiritide distributes rapidly to the extracellular fluid compartment. The volume of distribution at steady state is approximately 0.19 L/kg, consistent with primarily extracellular distribution. Plasma protein binding is minimal, as native BNP circulates predominantly in the unbound form [16].

Three clearance pathways. Nesiritide is cleared from the circulation through three approximately co-equal mechanisms [15][16]:

1. Neutral endopeptidase (neprilysin, NEP) degradation. NEP is a zinc-dependent metalloprotease expressed on the surface of vascular endothelial cells, renal tubular epithelium, and other tissues. It cleaves BNP at multiple sites within the peptide chain, including the disulfide ring, generating inactive fragments. NEP accounts for approximately one-third of total BNP clearance. This is the same enzyme inhibited by sacubitril in the neprilysin inhibitor sacubitril/valsartan (Entresto) [15][17].

2. NPR-C (clearance receptor) internalization. Natriuretic peptide receptor C (NPR-C) is a "decoy" receptor lacking guanylyl cyclase activity that binds all three natriuretic peptides (ANP, BNP, CNP), internalizes them via receptor-mediated endocytosis, and directs them to lysosomal degradation. NPR-C is widely expressed on vascular smooth muscle, endothelial cells, and kidney. This pathway accounts for approximately one-third of clearance [7][15].

3. Renal filtration. As a 3464 Da peptide with minimal protein binding, nesiritide is freely filtered at the glomerulus. Renal clearance contributes the remaining approximately one-third of total clearance. This pathway is clinically significant because reduced GFR (common in heart failure) prolongs nesiritide exposure and may increase hypotensive effects [15][16].

Half-life. The terminal elimination half-life is approximately 18-20 minutes, enabling rapid onset of hemodynamic effects within minutes of bolus administration and offset within 1-2 hours of infusion cessation. This short half-life is an advantage for managing hypotension (simply stop the infusion) but necessitates continuous infusion for sustained hemodynamic effect [16].

Steady-state pharmacokinetics. During continuous infusion at 0.01 mcg/kg/min, steady-state plasma BNP concentrations are approximately 3-6 times the endogenous BNP level in heart failure patients. The time to steady-state is approximately 60-90 minutes (3-5 half-lives). The 2 mcg/kg bolus is designed to achieve near-therapeutic concentrations immediately while the infusion approaches steady state [8][16].

Pharmacokinetic-pharmacodynamic relationship. The hemodynamic effects of nesiritide (PCWP reduction, SVR reduction, natriuresis) are directly proportional to plasma BNP concentrations over the therapeutic range. PCWP reduction begins within 15 minutes of bolus, reaches maximum at 1 hour, and is sustained during infusion at steady state. Following infusion cessation, hemodynamic parameters return to baseline within 2-4 hours [8][16].

Impact of Heart Failure on Pharmacokinetics

In patients with decompensated heart failure, nesiritide pharmacokinetics are altered in several important ways [16]:

• Reduced renal clearance: GFR is commonly reduced in ADHF (cardiorenal syndrome), prolonging nesiritide half-life to 20-25 minutes and increasing steady-state concentrations by approximately 20-40%
• Upregulated NPR-C expression: Chronic heart failure is associated with increased NPR-C expression, potentially increasing clearance receptor-mediated elimination and partially offsetting the reduced renal clearance
• Elevated endogenous BNP: Endogenous BNP levels in ADHF are already 10-100 fold above normal, and exogenous nesiritide adds to the total BNP pool. The therapeutic effect depends on the increment above the already elevated endogenous level
• NEP activity: Heart failure may alter neprilysin activity and expression, contributing to variable drug exposure

10. Dose-Response Relationships

Hemodynamic Dose-Response

The dose-response relationship of nesiritide for hemodynamic endpoints was established in the Phase 2 dose-ranging study (Colucci et al. 2000) and confirmed in the VMAC trial [1][8].

Dose-dependent PCWP reduction:

| Dose (mcg/kg/min infusion) | PCWP Reduction at 3 Hours | Mean Arterial Pressure Change | Cardiac Index Change | |---|---|---|---| | 0.003 (low dose) | -2.5 mmHg | -1.5 mmHg | +0.10 L/min/m2 | | 0.01 (standard dose) | -5.8 mmHg | -4.0 mmHg | +0.20 L/min/m2 | | 0.015 | -7.2 mmHg | -5.5 mmHg | +0.25 L/min/m2 | | 0.03 (maximum dose) | -9.0+ mmHg | -8.0+ mmHg | +0.30+ L/min/m2 |

The dose-response curve for PCWP reduction is approximately linear over the 0.003-0.03 mcg/kg/min range, with proportional increases in hemodynamic effect. However, the dose-response for hypotension is steeper at higher doses, with the incidence of symptomatic hypotension increasing disproportionately above 0.01 mcg/kg/min. This established 0.01 mcg/kg/min as the optimal starting infusion rate -- balancing meaningful hemodynamic improvement with acceptable hypotension risk [8][16].

Dyspnea Dose-Response

The relationship between nesiritide dose and symptomatic improvement (dyspnea) is less clearly dose-dependent than the hemodynamic effects. In ASCEND-HF, the standard dose (2 mcg/kg bolus + 0.01 mcg/kg/min) produced only modest dyspnea improvement (p=0.007 at 6 hours) despite meaningful PCWP reductions, highlighting the disconnect between hemodynamic surrogates and patient-centered symptoms [2].

The Bolus Question

The IV bolus (2 mcg/kg) was included in the dosing protocol to achieve rapid hemodynamic effects. However, the bolus is associated with the highest peak BNP concentrations and the greatest risk of immediate hypotension. In ASCEND-HF, the protocol allowed omission of the bolus at investigator discretion, and approximately 30% of patients received the infusion without a preceding bolus. Post-hoc analyses suggested that the bolus contributed to hypotension without clear additional symptomatic benefit, leading some clinicians to advocate for bolus-free protocols [2][16].

The ROSE-AHF trial tested a low-dose strategy (0.005 mcg/kg/min without bolus) specifically to explore whether a sub-hemodynamic dose might have renal-protective effects. This low-dose approach failed to improve either decongestion or renal function, effectively ruling out the "low-dose renal protection" hypothesis [10].

11. Comparative Effectiveness

Nesiritide vs. Nitroglycerin

The VMAC trial directly compared nesiritide with IV nitroglycerin, the traditional vasodilator for ADHF [1]:

| Parameter | Nesiritide (2 mcg/kg bolus + 0.01 mcg/kg/min) | Nitroglycerin (20 mcg/min titrated) | Difference | |---|---|---|---| | PCWP reduction at 3 hours | -5.8 mmHg | -3.8 mmHg | p=0.03 (NES superior) | | PCWP reduction at 24 hours | -8.2 mmHg | -6.3 mmHg | NS | | Dyspnea improvement at 3 hours | Significant vs placebo | Significant vs placebo | NS between agents | | Headache | 8% | 20% | NES favorable | | Hypotension | 11% | 6% | NTG favorable | | Tachyphylaxis | None | Common (within 24-48h) | NES favorable |

Nesiritide's hemodynamic advantages over nitroglycerin are modest and short-lived, largely limited to the first few hours. Nitroglycerin's advantages include lower hypotension risk, lower cost, and extensive clinical experience, though tachyphylaxis limits prolonged infusions. Most heart failure centers now preferentially use nitroglycerin for hypertensive ADHF presentations, reserving nesiritide for patients who develop nitroglycerin tachyphylaxis or headache [1][19].

Nesiritide vs. Milrinone/Dobutamine

Inotropes (milrinone, dobutamine) represent the primary alternative to vasodilators in ADHF with low cardiac output [9][19]:

| Parameter | Nesiritide | Milrinone | Dobutamine | |---|---|---|---| | Mechanism | NPR-A/cGMP vasodilation | PDE3 inhibition (inotrope + vasodilator) | Beta-1 agonist (inotrope) | | Cardiac output | Modest increase (via afterload reduction) | Significant increase (direct inotropy) | Significant increase (direct inotropy) | | Arrhythmia risk | Low (1% VT in PRECEDENT) | Moderate (12% sustained VT) | Moderate (12% VT in PRECEDENT) | | Hypotension | Common (26.6% in ASCEND-HF) | Common | Less common (BP maintained by CO increase) | | Mortality signal | None (ASCEND-HF) | Possible increase (OPTIME-CHF, NS trend) | Uncertain (no large RCTs) | | Optimal patient | Elevated SVR, adequate BP, congestion | Low CO with congestion | Low CO, hypotensive | | Cost | High (~$500/day) | Moderate (~$100/day generic) | Low (~$10-20/day generic) |

The PRECEDENT trial showed that nesiritide produced fewer ventricular arrhythmias than dobutamine (1% vs 12%, p=0.001), suggesting a safety advantage in patients at risk for arrhythmia [9]. However, nesiritide cannot provide the direct inotropic support needed in cardiogenic shock, limiting its utility to the hemodynamically stable congested patient.

The ASCEND-HF Failure in Context

ASCEND-HF (n=7,141) definitively showed that nesiritide, despite producing measurable hemodynamic improvements and modest dyspnea relief, does not reduce 30-day mortality or heart failure rehospitalization -- the hard endpoints that define clinical value in acute heart failure [2]. This result must be understood in context:

• The comparator problem: Placebo-treated patients in ASCEND-HF received standard of care including IV diuretics, which are the mainstay of ADHF treatment. Nesiritide's marginal additional benefit suggests that the hemodynamic effects achievable with aggressive diuresis are difficult to improve upon.
• The natriuretic peptide paradox: While exogenous BNP administration (nesiritide) failed, inhibition of endogenous BNP degradation (sacubitril/valsartan) succeeded dramatically in PARADIGM-HF, reducing cardiovascular death by 20%. This suggests that the pattern, timing, and tissue distribution of endogenous natriuretic peptide signaling cannot be replicated by bolus-and-infusion exogenous administration [17].
• The DOSE trial paradigm: Published the same year as ASCEND-HF, the DOSE trial showed that optimized high-dose IV furosemide is the cornerstone of ADHF management, further marginalizing the need for adjunctive vasodilators [18].

12. Enhanced Safety Profile

Comprehensive Safety Analysis from ASCEND-HF

The ASCEND-HF trial (n=7,141) provides the most comprehensive safety dataset for nesiritide and definitively resolved the safety concerns raised by the 2005 meta-analyses [2][3][4].

Mortality (safety definitively established):

| Endpoint | Nesiritide (n=3,496) | Placebo (n=3,506) | HR (95% CI) | P-value | |---|---|---|---|---| | 30-day all-cause mortality | 3.6% | 4.0% | 0.90 (0.68-1.18) | 0.44 | | 180-day all-cause mortality | 10.1% | 10.5% | 0.96 (0.82-1.12) | 0.60 |

These data conclusively refute the Sackner-Bernstein meta-analysis mortality signal (RR 1.74, p=0.059) and establish that nesiritide does not increase short-term or medium-term mortality [2][4].

Renal function (safety definitively established):

| Endpoint | Nesiritide | Placebo | P-value | |---|---|---|---| | Worsening renal function (Cr increase of 0.5 mg/dL or more) | 31.4% | 31.0% | 0.89 | | Dialysis requirement | 0.5% | 0.4% | NS | | Mean change in serum creatinine | +0.05 mg/dL | +0.04 mg/dL | NS |

These data conclusively refute the Sackner-Bernstein renal risk meta-analysis (RR 1.52, p=0.003) and establish that nesiritide does not worsen renal function compared to standard care [2][3].

Hypotension -- the primary real safety concern:

| Hypotension Parameter | Nesiritide | Placebo | Significance | |---|---|---|---| | Any hypotension (SBP below 90 mmHg) | 26.6% | 15.3% | Significantly higher | | Symptomatic hypotension requiring intervention | 7.1% | 4.2% | Significantly higher | | Hypotension leading to treatment discontinuation | 4.8% | 2.1% | Significantly higher | | Hypotension causing end-organ injury | rare | rare | No difference |

Hypotension is the principal real adverse effect of nesiritide, occurring in approximately one-quarter of patients and requiring dose reduction or discontinuation in approximately 5%. The risk is highest in the first hour after bolus, in patients with systolic BP below 110 mmHg at baseline, and in volume-depleted patients [2][16].

Risk Mitigation Strategies

Based on ASCEND-HF safety data, the following strategies minimize hypotension risk [16]:

1. Avoid nesiritide when SBP is below 100 mmHg (labeled contraindication at SBP below 90 mmHg, but many clinicians use 100 mmHg as a practical threshold)
2. Consider omitting the bolus -- start with infusion alone at 0.01 mcg/kg/min to avoid peak hypotensive effect
3. Close blood pressure monitoring -- every 15 minutes for the first hour, then hourly during infusion
4. Volume status optimization -- ensure adequate volume resuscitation before initiation; nesiritide in volume-depleted patients produces exaggerated hypotension
5. Short infusion duration -- limit to 24-48 hours maximum; no evidence supports longer infusions

The Lessons of Safety Controversy

The nesiritide safety narrative provides important methodological lessons [2][3][4][12]:

• Meta-analyses of small trials can generate false signals. The 2005 meta-analyses were based on only 862-1,269 patients with heterogeneous inclusion criteria, different nesiritide doses, and varying comparators. Despite meeting traditional statistical thresholds, both signals were refuted by the definitive 7,141-patient ASCEND-HF trial.
• Post hoc analyses should be hypothesis-generating, not practice-changing. The rapid and dramatic decline in nesiritide use following the 2005 publications (from approximately $700 million to approximately $100 million annual sales) occurred before definitive evidence was available [13].
• Large pragmatic outcomes trials are essential for safety assessment. Only ASCEND-HF had sufficient power to exclude clinically meaningful harm.

13. Regulatory Status

United States (FDA). Natrecor (nesiritide) was approved in August 2001 for intravenous treatment of patients with acutely decompensated heart failure with dyspnea at rest or minimal activity [16]. In February 2018, Janssen Pharmaceuticals announced discontinuation of nesiritide manufacturing, effectively ending its commercial availability in the United States. The discontinuation was driven by declining clinical use following the ASCEND-HF results and the shift toward sacubitril/valsartan-based heart failure management. As of 2026, nesiritide is no longer commercially available.

Manufacturer. Originally developed by Scios Inc., acquired by Johnson and Johnson in 2003 for approximately $2.4 billion. Marketed through Janssen Pharmaceuticals until manufacturing discontinuation in 2018.

14. Related Peptides

See also: Vasoactive Intestinal Peptide (VIP), Bradykinin, Endothelin-1

15. References

1. [1] Publication Committee for the VMAC Investigators. (2002). Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure. JAMA. DOI PubMed
2. [2] O'Connor CM, Starling RC, Hernandez AF, et al. (2011). Effect of Nesiritide in Patients with Acute Decompensated Heart Failure (ASCEND-HF). N Engl J Med. DOI PubMed
3. [3] Sackner-Bernstein JD, Skopicki HA, Aaronson KD. (2005). Risk of Worsening Renal Function with Nesiritide in Patients with Acutely Decompensated Heart Failure. Circulation. DOI PubMed
4. [4] Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson KD. (2005). Short-Term Risk of Death After Treatment with Nesiritide for Decompensated Heart Failure. JAMA. DOI PubMed
5. [5] Yancy CW, Krum H, Massie BM, et al. (2008). Safety and Efficacy of Outpatient Nesiritide in Patients with Advanced Heart Failure -- Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial. Circ Heart Fail. DOI PubMed
6. [6] Sudoh T, Kangawa K, Minamino N, Matsuo H. (1988). A New Natriuretic Peptide in Porcine Brain. Nature. DOI PubMed
7. [7] Potter LR, Abbey-Hosch S, Bhatt DK. (2009). Natriuretic Peptide Receptors: Structure, Function and Regulation. Handb Exp Pharmacol. DOI PubMed
8. [8] Colucci WS, Elkayam U, Horton DP, et al. (2000). Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure. N Engl J Med. DOI PubMed
9. [9] Silver MA, Horton DP, Ghali JK, Elkayam U. (2002). Effect of Nesiritide versus Dobutamine on Short-Term Outcomes in the Treatment of Patients with Acutely Decompensated Heart Failure (PRECEDENT). J Am Coll Cardiol. DOI PubMed
10. [10] Chen HH, Anstrom KJ, Givertz MM, et al. (2013). Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure with Renal Dysfunction -- The ROSE Acute Heart Failure Randomized Trial. JAMA. DOI PubMed
11. [11] Hernandez AF, O'Connor CM, Starling RC, et al. (2009). Rationale and Design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. DOI PubMed
12. [12] Topol EJ. (2005). Nesiritide -- Not Verified. N Engl J Med. DOI PubMed
13. [13] Hauptman PJ, Schnitzler MA, Swindle JP, Burroughs TE. (2006). Use of Nesiritide Before and After Publications Suggesting Drug-Related Risks in Patients with Acute Decompensated Heart Failure. JAMA. DOI PubMed
14. [14] de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. (1981). A Rapid and Potent Natriuretic Response to Intravenous Injection of Atrial Myocardial Extract in Rats. Life Sci. DOI PubMed
15. [15] Levin ER, Gardner DG, Samson WK. (1998). Natriuretic Peptides. N Engl J Med. DOI PubMed
16. [16] Natrecor Prescribing Information (2022). Natrecor (Nesiritide) for Injection: Full Prescribing Information. Scios / Janssen / FDA. PubMed
17. [17] McMurray JJ, Packer M, Desai AS, et al. (2014). Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF). N Engl J Med. DOI PubMed
18. [18] Felker GM, Lee KL, Bull DA, et al. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure (DOSE). N Engl J Med. DOI PubMed
19. [19] Yancy CW, Jessup M, Bozkurt B, et al. (2013). 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. DOI PubMed
20. [20] Ezekowitz JA, O'Meara E, McDonald MA, et al. (2017). 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. DOI PubMed